Frankfurt
20.12.24
08:06 Uhr
53,00 Euro
0,00
0,00 %
0,00 %
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 29.11. | Novonesis (Novozymes A/S): Major shareholder announcement | 28 | GlobeNewswire (USA) | ||
| 25.11. | Novonesis (Novozymes A/S): Major shareholder announcement | 6 | GlobeNewswire (USA) | ||
| 20.11. | Novonesis (Novozymes A/S): Trading by management and close relations of management | 15 | GlobeNewswire (USA) | ||
| 13.11. | Novonesis (Novozymes A/S): Major shareholder announcement | 22 | GlobeNewswire (USA) | ||
| NOVONESIS A/S ADR Aktie jetzt für 0€ handeln | |||||
| 07.11. | Novonesis (Novozymes A/S): Q3 update: Novonesis delivers strong Q3 results and now expects full-year organic sales growth at the upper end of 7-8% | 428 | GlobeNewswire (Europe) | Following increasing demand in the first nine months of the 2024 financial year, Novonesis delivers 9% organic sales growth with a strong 11% organic sales growth in the third quarter. The strong performance... ► Artikel lesen | |
| 04.11. | Novonesis (Novozymes A/S): Trading by management and close relations of management | 23 | GlobeNewswire (USA) | ||
| 23.10. | Novonesis (Novozymes A/S): Major shareholder announcement | 20 | GlobeNewswire (USA) | ||
| 21.10. | Novonesis (Novozymes A/S): New employee-elected board member | 6 | GlobeNewswire (USA) | ||
| 17.10. | Citi stuft Novozymes-Aktie auf Verkaufen herab und erwartet Verfehlung der mittelfristigen Ziele | 34 | Investing.com Deutsch | ||
| 16.10. | Novonesis (Novozymes A/S): Trading by management and close relations of management | 14 | GlobeNewswire (USA) | ||
| 15.10. | Novonesis (Novozymes A/S): Major shareholder announcement | 17 | GlobeNewswire (USA) | ||
| 09.10. | Novonesis (Novozymes A/S): Major shareholder announcement | 5 | GlobeNewswire (USA) | ||
| 03.10. | Novonesis (Novozymes A/S): Major shareholder announcement | 8 | GlobeNewswire (USA) | ||
| 16.09. | Novonesis (Novozymes A/S): Trading by management and close relations of management | 12 | GlobeNewswire (USA) | ||
| 11.09. | Novonesis (Novozymes A/S): Trading by management and close relations of management | 7 | GlobeNewswire (USA) | ||
| 10.09. | Novonesis (Novozymes A/S): Major shareholder announcement | 7 | GlobeNewswire (USA) | ||
| 09.09. | Dividendenbekanntmachungen (09.09.2024) | 5.907 | wallstreetONLINE (Dividenden) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ADMIE IPTO HOLDING SA GRS518003009 - 0,0582 EUR AFRICA OIL CORP CA00829Q1019 0,025 USD 0,0225 EUR ALEXANDERWERK AG DE000A37FTW0 - 1... ► Artikel lesen | |
| 05.09. | Novozymes A/S: Major shareholder announcement | 10 | GlobeNewswire (USA) | ||
| 30.08. | Novozymes A/S: Trading by management and close relations of management | 6 | GlobeNewswire (USA) | ||
| 29.08. | Novozymes A/S: Major shareholder announcement | 7 | GlobeNewswire (USA) |
Seite:
1 2 3 Weiter >>
44 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ADMA BIOLOGICS | 17,400 | -2,68 % | ADMA Biologics, Inc.: ADMA Biologics Announces Partial Paydown of Senior Term Loan Credit Facility | ||
| QIAGEN | 42,900 | +0,04 % | Sartorius, Qiagen, Siemens Energy, DHL Group, Adidas, Puma: DAX-Ausblick | Nach seiner jüngsten Rekordjagd hat der DAX in der abgelaufenen Woche etwas Luft geholt. Unter dem Strich legte das größte deutsche Börsenbarometer trotzdem 21 Punkte zu und schloss mit knapp 20.406... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 76,52 | +5,05 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet Syndrome | Dravet syndrome is a genetic developmental and epileptic encephalopathy (DEE) often caused by a mutation in SCN1A This is the third Rare Pediatric Disease Designation for relutrigine, adding to those... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 14,990 | +6,24 % | Arcutis Biotherapeutics, Inc.: Arcutis Submits ZORYVE (roflumilast) Cream 0.05% Supplemental New Drug Application to the FDA for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis | ZORYVE cream 0.05% provided meaningful disease clearance and rapid reduction in itch in pivotal trialsRoflumilast cream was well tolerated and demonstrated a favorable safety and tolerability profile... ► Artikel lesen | |
| EVOTEC | 8,405 | +1,08 % | Evotec Aktie: Beeindruckende Entwicklung! | Die Evotec-Aktie zeigt im aktuellen Börsenumfeld erste Anzeichen einer Stabilisierung. Nach einem herausfordernden Jahr 2024 mit einem Rückgang von fast 60 Prozent konnte sich das Papier zuletzt von... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 7,340 | -0,27 % | Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update | SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the third quarter ended September 30, 2024.
"This quarter... ► Artikel lesen | |
| CELCUITY | 12,460 | +3,83 % | Celcuity Inc.: Celcuity Presents Overall Survival Data from Phase 1b Study Evaluating Gedatolisib in Combination with Palbociclib and Endocrine Therapy at the 2024 San Antonio Breast Cancer Symposium | Median overall survival (OS) among patients with HR+, HER2- advanced breast cancer who were treatment-naïve in the advanced setting was 77.3 months Median OS among patients previously treated with... ► Artikel lesen | |
| CONTINEUM THERAPEUTICS | 13,500 | +1,12 % | Contineum Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights | SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that... ► Artikel lesen | |
| BIONTECH | 108,60 | +0,09 % | Abstieg und Hoffnung: So steht es um den BioNTech-Konkurrenten Moderna | Die Aktie von Moderna hat in den vergangenen zwölf Monaten eine enttäuschende Entwicklung hingelegt. Im Nasdaq 100 gehört sie in diesem Zeitraum zu den zwei schlechtesten Werten. Nun muss sie den Index... ► Artikel lesen | |
| HUMACYTE | 4,635 | +33,77 % | Pre-market Movers: My Size, Nvni Group, Psyence Biomedical, Humacyte, PainReform | BRASILIA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 07.55 A.M. ET).In the Green My Size, Inc. (MYSZ) is up over 372% at $6.43.
Nvni... ► Artikel lesen | |
| AMGEN | 252,90 | +0,18 % | What's Going On With Amgen Stock On Friday? | ||
| JANUX THERAPEUTICS | 56,70 | -0,09 % | Pre-market Movers: Cheetah Net Supply Chain Service, NLS Pharmaceutics, PSQ Holdings, Janux Therapeutics, Coherus BioSciences | CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 08.45 A.M. ET).In the Green Cheetah Net Supply Chain Service Inc. (CTNT) is up... ► Artikel lesen | |
| FOGHORN THERAPEUTICS | 5,140 | +3,21 % | Foghorn Therapeutics, Inc.: Foghorn Therapeutics Provides Update on FHD-286 Clinical Development Program and Strategic Priorities | Objective clinical responses by standard response criteria observed in Phase 1 dose escalation trial for FHD-286 in combination with decitabine in patients with relapsed and/or refractory AML; efficacy... ► Artikel lesen | |
| IMMUNOVANT | 25,880 | +0,86 % | Immunovant (NASDAQ:IMVT) Trading Down 5.2% - Here's Why | ||
| RECURSION PHARMACEUTICALS | 6,035 | -0,90 % | Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules | Salt Lake City, Utah, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. ("Recursion") (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug... ► Artikel lesen |
NOVONESIS A/S ADR gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 53,00 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NOVONESIS A/S ADR finden Sie auf Wallstreet Online.
